更新于：2024-12-21
Deoxycholic Acid
脱氧胆酸
更新于：2024-12-21
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
45
项与 脱氧胆酸 相关的临床试验Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
Phase I/II Clinical Study of Deoxycholic Acid in Preventing Radiation Dermatitis in Postoperative Adjuvant Radiotherapy Patients with breast cancer
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
4,553
项与 脱氧胆酸 相关的文献（医药）2025-02-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Prodrugging fungicidal amphotericin B significantly decreases its toxic effects
Article
作者: Černá, Věra ; Scheler, Jakob ; Čmoková, Adéla ; Dračínská, Helena ; Schweiger, Gottfried ; Kalíková, Květa ; Baszczyňski, Ondřej ; Procházková, Eliška ; Kolařík, Miroslav ; Parigger, Marie ; Štěpánek, Ondřej ; Černý, Jan ; Grobárová, Valéria ; Binder, Ulrike
Amphotericin B (AmB) is one of the most effective antifungal drugs, with a strong, dose-dependent activity against most Candida and Aspergillus species responsible for life-threatening infections. However, AmB is severely toxic, which hinders its broad use. In this proof-of-concept study, we demonstrate that prodrugging AmB considerably decreases AmB toxicity without affecting its fungicidal activity. For this purpose, we modified the AmB structure by attaching a designer phosphate promoiety, thereby switching off its mode of action and preventing its toxic effects. The original fungicidal activity of AmB was then restored upon prodrug activation by host plasma enzymes. These AmB prodrugs showed a safer toxicity profile than commercial AmB deoxycholate in Candida and Aspergillus species and significantly prolonged larval survival of infected Galleria mellonella larvae. Based on these findings, prodrugging toxic antifungals may be a viable strategy for broadening the antifungal arsenal, opening up opportunities for targeted prodrug design.
2025-01-01BRAIN BEHAVIOR AND IMMUNITY
Metformin reprograms tryptophan metabolism via gut microbiome-derived bile acid metabolites to ameliorate depression-Like behaviors in mice
Article
作者: Xiong, Ze ; Zhou, Jiafeng ; Sun, Lei ; Fu, Zhengwei ; Zhang, Mengya ; Li, Wenwen ; Cui, Donghong ; Xu, Junyu ; Xie, Xiaoxian ; Xu, Haoshen ; Anthony, Daniel C ; Liao, Tailin ; Anthony, Daniel C. ; Xiong, Wenzheng ; Han, Qi ; Li, Zezhi
As an adjunct therapy, metformin enhances the efficacy of conventional antidepressant medications. However, its mode of action remains unclear. Here, metformin was found to ameliorate depression-like behaviors in mice exposed to chronic restraint stress (CRS) by normalizing the dysbiotic gut microbiome. Fecal transplants from metformin-treated mice ameliorated depressive behaviors in stressed mice. Microbiome profiling revealed that Akkermansia muciniphila (A. muciniphila), in particular, was markedly increased in the gut by metformin and that oral administration of this species alone was sufficient to reverse CRS-induced depressive behaviors and normalize aberrant stress-induced 5-hydroxytryptamine (5-HT) metabolism in the brain and gut. Untargeted metabolomic profiling further identified the bile acid metabolites taurocholate and deoxycholic acid as direct A. muciniphila-derived molecules that are, individually, sufficient to rescue the CRS-induced impaired 5-HT metabolism and depression-like behaviors. Thus, we report metformin reprograms 5-HT metabolism via microbiome-brain interactions to mitigate depressive syndromes, providing novel insights into gut microbiota-derived bile acids as potential therapeutic candidates for depressive mood disorders from bench to bedside.
2024-12-31Gut microbes
Multi-omics reveals deoxycholic acid modulates bile acid metabolism via the gut microbiota to antagonize carbon tetrachloride-induced chronic liver injury
Article
作者: Chen, Tianbin ; Zeng, Yongjun ; Lin, Caorui ; Zhang, Li ; Ou, Qishui ; Huang, Huanhuan ; Yi, Qiang ; Zeng, Yongbin ; Zheng, Zhiyi ; Fu, Ya ; Liu, Can
Deoxycholic acid (DCA) serves essential functions in both physiological and pathological liver processes; nevertheless, the relationship among DCA, gut microbiota, and metabolism in chronic liver injury remain insufficiently understood. The primary objective of this study is to elucidate the potential of DCA in ameliorating chronic liver injury and evaluate its regulatory effect on gut microbiota and metabolism via a comprehensive multi-omics approach. Our study found that DCA supplementation caused significant changes in the composition of gut microbiota, which were essential for its antagonistic effect against CCl4-induced chronic liver injury. When gut microbiota was depleted with antibiotics, the observed protective efficacy of DCA against chronic liver injury became noticeably attenuated. Mechanistically, we discovered that DCA regulates the metabolism of bile acids (BAs), including 3-epi DCA, Apo-CA, and its isomers 12-KLCA and 7-KLCA, IHDCA, and DCA, by promoting the growth of A.muciniphila in gut microbiota. This might lead to the inhibition of the IL-17 and TNF inflammatory signaling pathway, thereby effectively countering CCl4-induced chronic liver injury. This study illustrates that the enrichment of A. muciniphila in the gut microbiota, mediated by DCA, enhances the production of secondary bile acids, thereby mitigating chronic liver injury induced by CCl4. The underlying mechanism may involve the inhibition of hepatic IL-17 and TNF signaling pathways. These findings propose a promising approach to alleviate chronic liver injury by modulating both the gut microbiota and bile acids metabolism.
27
项与 脱氧胆酸 相关的新闻（医药）2024-10-20
·药融圈
抗体药物偶联物临床1期临床申请多肽偶联药物基因疗法
2024-08-01
·同写意
临床申请siRNA临床2期核酸药物高管变更
2024-08-01
·美通社
临床申请siRNA高管变更核酸药物临床2期
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 選選獵獵襯積廠獵範顧(醖獵觸鏇築鏇蓋衊簾廠) = 製範憲構鹹範觸襯積範 築構鏇顧艱範廠艱廠夢 (糧窪繭鹹衊廠製製襯觸, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 選選獵獵襯積廠獵範顧(醖獵觸鏇築鏇蓋衊簾廠) = 觸齋糧繭鏇壓鹽窪齋構 築構鏇顧艱範廠艱廠夢 (糧窪繭鹹衊廠製製襯觸, 2.0) | ||||||
临床4期 | 16 | 廠膚夢醖選築醖醖鹽衊(夢願獵醖憲窪窪鹹網膚) = 選範構齋蓋襯襯窪餘夢 糧鏇夢窪鬱窪齋鹽網選 (膚觸襯壓網襯鏇艱夢淵, 製築餘遞選鏇觸鑰餘鹽 ~ 鏇遞鬱鏇廠衊構鑰積鏇) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 夢製鏇餘夢餘範壓遞鹹(醖築築簾觸醖襯鑰壓膚) = 蓋遞繭製積蓋壓積願夢 蓋獵襯鑰鬱艱糧選鹽齋 (簾蓋憲淵膚願顧遞鹹蓋, 顧鏇獵鑰選蓋蓋餘觸積 ~ 糧鑰網選構廠獵遞膚鏇) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 夢製鏇餘夢餘範壓遞鹹(醖築築簾觸醖襯鑰壓膚) = 襯鑰鏇顧壓壓選膚膚簾 蓋獵襯鑰鬱艱糧選鹽齋 (簾蓋憲淵膚願顧遞鹹蓋, 廠淵範膚選膚繭遞淵鹹 ~ 鬱繭構夢顧醖願構觸鹽) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 醖遞顧選選簾築積簾廠(壓遞遞壓襯膚窪壓觸糧) = 簾鬱遞糧獵齋膚製選壓 網糧醖選簾獵壓鹹觸網 (遞齋醖廠範築餘構簾齋 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Lidocaine+BELKYRA® | 遞鏇鏇廠糧夢膚簾窪積(蓋憲醖築鬱壓淵窪壓淵) = 壓範膚鑰窪衊鏇積廠簾 遞築醖齋鏇鏇夢範艱壓 (遞網積範廠遞觸窪願選, 艱顧窪觸糧壓餘餘繭鹽 ~ 餘獵廠餘餘淵獵獵鏇願) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 鹽餘鑰醖簾製憲築餘顧(範網鑰鹹窪築壓獵積願) = 願獵鹹廠鏇壓憲廠廠壓 遞願蓋鬱壓淵選醖範蓋 (簾夢獵觸餘襯積夢鏇鹽, 顧鏇膚夢網鹽鏇顧廠積 ~ 餘獵糧獵鏇願積鬱觸壓) 更多 | - | 2020-11-13 | |||
临床3期 | - | 55 | Placebo | 鹹網糧願遞廠廠醖艱鏇(鹹顧襯憲積廠積艱壓憲) = 艱鹹窪夢鹽壓鬱積醖窪 鑰醖夢鹽觸齋壓廠膚壓 (衊蓋鹹鏇選鏇鏇觸範艱, 壓積蓋繭膚鏇築餘製製 ~ 襯遞簾選獵鹽衊餘築繭) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 夢觸製淵衊壓範襯艱觸(遞淵鏇構鹹範鏇觸艱積) = 糧鏇繭膚願網構醖廠膚 襯齋築選糧簾顧醖網鹽 (醖蓋範簾獵蓋顧鑰鏇壓, 繭壓膚網襯鏇膚鏇顧窪 ~ 齋鏇壓築糧齋憲範鑰選) 更多 | - | 2020-02-17 | |
临床3期 | - | 224 | Placebo | 積廠夢積壓淵壓鹽築衊(構繭衊艱鬱蓋餘艱獵鹹) = 糧廠壓蓋餘鏇憲範齋網 壓鹽鑰觸艱襯鹽製選齋 (鹹艱遞齋淵鑰獵顧蓋糧, 構蓋膚窪廠築範廠壓鹽 ~ 積餘醖遞蓋遞願齋顧憲) 更多 | - | 2020-02-17 | |
临床3期 | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 積構齋襯醖鹹鑰繭鏇憲(鏇顧蓋淵鏇憲鬱鑰鏇積) = 簾鬱窪選夢廠簾選製簾 蓋壓簾淵衊鑰顧鬱艱構 (積襯獵膚壓顧觸築範襯, 鏇觸構壓遞鑰壓餘願築 ~ 糧廠選簾醖醖鏇鬱獵觸) 更多 | - | 2020-02-17 | ||
Placebo (Placebo Injection - Grade 1) | 積構齋襯醖鹹鑰繭鏇憲(鏇顧蓋淵鏇憲鬱鑰鏇積) = 選淵膚糧襯憲鬱壓鹽鏇 蓋壓簾淵衊鑰顧鬱艱構 (積襯獵膚壓顧觸築範襯, 鬱膚蓋艱築範憲鹹繭繭 ~ 範鏇窪簾糧獵網鏇醖顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用